Recombinant Human Deoxyribonuclease in Infants With Respiratory Syncytial Virus Bronchiolitis

Authors :: Boogaard, Ruben
Hulsmann, Anthon R.
van Veen, Leoniek
Vaessen-Verberne, Anja A.P.H.
Yap, Yen Ni
Sprij, Arwen J.
Brinkhorst, Govert
Sibbles, Barbara
Hendriks, Tom
Feith, Sander W.W.
Lincke, Carsten R.
Brandsma, Annelies E.
Brand, Paul L.P.
Hop, Wim C.J.
de Hoog, Matthijs
Merkus, Peter J.F.M.
Source :: Chest; March 2007, Vol. 131 Issue: 3 p788-795, 8p
Publication Year :: 2007
Abstract: Background:Treatment of hospitalized infants with respiratory syncytial virus (RSV) bronchiolitis is mainly supportive. Bronchodilators and systemic steroids are often used but do not reduce the length of hospital stay. Because hypoxia and airways obstruction develop secondary to viscous mucus in infants with RSV bronchiolitis, and because free DNA is present in RSV mucus, we tested the efficacy of the mucolytic drug recombinant human deoxyribonuclease (rhDNase).

Full Text Access

Tools